Abstract: Objective The aim of this study was to investigate the clinical efficacy of sofosbuvir and velpatasvir combination regimen in the treatment of patients with hepatitis C-induced liver cirrhosisand its influence on ultrasonic indexes of portal vain. Methods 54 patients with hepatitis C-induced liver cirrhosis, including compensated in 31 cases and decompensated in 23 cases, were enrolled in our hospital between June 2021 and June 2024, patients with compensated liver cirrhosis received sofosbuvir and velpatasvir combination, and those with decompensated liver cirrhosis received ribavirin at base of sofosbuvir and velpatasvir combination. Antiviral therapy lasted for 12 weeks. Serum HCV RNA loads were detected by fluorescenct quantitative RT-PCR, and serum hyaluronic acid (HA), type III procollagen (PCIII), type IV collagen (IV-C) and laminin (LN) levels were assayed immunoradiometric assay. Liver stiffness measurement (LSM), portal vein diameter (PVD) and spleen thickness (ST) were measured by Fibrotouch or ultrasonic diagnostic instrument. Results The sustained viral response (SVR) rate in our series was 94.4%, all but one with HCV genotype 1 and two with HCV genotype 3 responded completely to the antiviral therapy; virological response rate in patients with compensated cirrhosis at month one, month three and three months after discontinuation of antiviral therapy were all 100.0%, while in those with decompensated cirrhosis were 78.3%, 82.6% and 87.0%, respectively; after treatment, serum HA, PCⅢ and Ⅳ-C levels in patients with compensated cirrhosis were (92.6±21.4)μg/L, (127.2±28.4)μg/Land (105.6±26.8)μg/L, all significantly lower than [(139.4±35.8)μg/L, (197.6±34.8)μg/Land (166.2±32.9)μg/L, respectively, P<0.05] in those with decompensated cirrhosis; LSM and PVD were (18.2±2.1) kPa and (13.4±1.3)mm, both much less than [(20.7±2.3)kPa and (15.8±1.1)mm, respectively, P<0.05] in those with decompensated cirrhosis. Conclusion Sofosbuvir and velpatasvir combination with or without ribavirin in the treatment of patients with hepatitis C-induced liver cirrhosis is efficacious, which warrants further clinical observation.

Key words: Liver cirrhosis, Hepatitis C, Sofosbuvir, Velpatasvir, Therapy